Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/4e485f20-5bcd-4227-ba9f-a2f7dccfc287
Business
Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/4e485f20-5bcd-4227-ba9f-a2f7dccfc287
One fund targets life sciences in the United States and Europe; the other will pursue healthcare investments across Asia.
The company expects revenue of $65 million to $125 million and an Adjusted EBITDA loss of $510 million to $565 million.
The company expects data from three radiotherapy studies in the fourth quarter of 2026 and during 2027 as it works under an NYSE American compliance plan.